The next treatment after chemotherapy depends on how well the cancer responded, what type of cancer you have, and the overall goal of your care. For some people, the next step is maintenance therapy to keep the cancer from returning. For others, it may be radiation, surgery, immunotherapy, a stem cell transplant, or a different chemotherapy regimen. There is no single path forward, but understanding the main options can help you make sense of what your oncology team recommends.
Maintenance Therapy
If chemotherapy shrank your tumor or stopped it from growing, your doctor may recommend maintenance therapy. This isn’t the same as another round of chemo. The goal shifts from aggressively killing cancer cells to sustaining the progress already made and delaying the return of symptoms. Maintenance therapy typically begins after four to six cycles of first-line chemotherapy and continues until the cancer progresses or side effects become unmanageable.
There are two general approaches. Continuous maintenance keeps you on one or more drugs from your original chemotherapy regimen, usually at a more tolerable dose. Switch maintenance moves you to a completely different drug, one that works through a different mechanism so the cancer is less likely to resist it. Both strategies are well established in advanced lung cancer and are increasingly used in ovarian and other cancers.
Targeted Therapy and Immunotherapy
Biomarker testing on your tumor tissue can reveal whether a targeted therapy or immunotherapy drug is a good fit. These treatments zero in on specific features of cancer cells rather than attacking all rapidly dividing cells the way traditional chemo does.
A few examples illustrate how this works in practice. If your tumor has a DNA repair defect called mismatch repair deficiency, a type of immunotherapy that blocks a protein called PD-1 may be effective. The drug pembrolizumab has been approved for solid tumors with this defect after they progress on prior treatment. If your cancer overproduces a protein called HER2, an antibody-drug conjugate called fam-trastuzumab deruxtecan has shown response rates of about 70% in previously treated metastatic breast cancer, compared to 29% with standard chemo. In 2024, the FDA expanded its approval to any previously treated advanced cancer that tests strongly positive for HER2.
Your oncologist will typically order biomarker testing if it hasn’t been done already. The results guide which drugs, if any, are likely to work for your specific tumor biology.
Radiation Therapy After Chemo
Radiation is a common next step when chemotherapy is used to shrink a tumor before local treatment, or when the goal is to eliminate remaining cancer cells after surgery. In breast cancer, for example, post-mastectomy radiation ideally begins within 42 days of finishing chemotherapy. Waiting longer than that has been linked to roughly double the risk of distant spread and significantly lower overall survival in high-risk patients. Your radiation oncologist will work to schedule treatment within this window.
Radiation can also serve as a standalone follow-up to chemo for cancers in the head, neck, pelvis, or brain where surgery isn’t practical. The number of sessions varies widely, from a handful of high-dose treatments to daily sessions over several weeks.
Surgery
When chemotherapy is given before surgery (called neoadjuvant chemotherapy), the goal is to shrink the tumor enough to make a complete removal possible. If imaging after chemo shows the tumor has responded well, surgery is usually scheduled within a few weeks. The surgeon removes the remaining tumor along with a margin of healthy tissue, and a pathologist examines the sample to see how much cancer, if any, survived the chemo. That pathology report often determines whether additional treatment is needed afterward.
Second-Line Chemotherapy
If the cancer didn’t respond to the first round of chemo, or if it came back quickly, a different chemotherapy regimen is usually the next consideration. How your cancer behaved during first-line treatment matters a great deal here.
Cancers that initially responded and stayed in remission for more than six months are considered “chemosensitive.” In these cases, retreatment with the original regimen is often effective. Cancers that never responded, or that returned within 90 days of finishing treatment, are classified as refractory or resistant. These require a different drug or combination, since the original regimen clearly isn’t working. For small cell lung cancer, for instance, only one drug (topotecan) is specifically approved as a second-line option in the U.S., though several others are used in combination or through clinical trials.
Stem Cell Transplants
For blood cancers like leukemia, lymphoma, and myeloma, a stem cell transplant may follow chemotherapy. High-dose chemo wipes out the bone marrow, and then stem cells are infused to rebuild it. The transplant can use your own stem cells (collected before the high-dose chemo) or cells from a donor.
Which type you receive depends on several factors: your age, the type and stage of cancer, whether there’s a matched donor available, and how well the cancer responded to prior chemo. Responsiveness to conventional chemotherapy is one of the strongest predictors of transplant success. Patients who achieve at least a partial response, or who transplant while their disease burden is minimal, tend to have the best outcomes. Those with bulky disease that hasn’t responded to treatment, or who have relapsed multiple times, face a more difficult road.
Transplants are generally recommended early in the disease course for cancers at high risk of relapse, or shortly after the first recurrence rather than after multiple failed treatments.
Clinical Trials
When standard options have been exhausted, or when a cancer proves resistant to available treatments, clinical trials offer access to new drugs and approaches. Eligibility varies by trial, but common requirements include documented progression on prior therapy, adequate organ function, and a specific cancer type or biomarker profile. Some trials are open to patients whose cancer returned quickly after chemo, while others require a longer remission period first.
Your oncologist can search trial databases for options matched to your diagnosis. Many major cancer centers have dedicated staff to help identify and enroll patients in appropriate studies.
Monitoring Without Active Treatment
If chemo was successful and no further treatment is needed right away, you’ll enter a surveillance phase. For many cancers, the first imaging scan happens three to six months after treatment ends to assess the response. After that, the schedule depends on your cancer type and risk level. In advanced head and neck cancer, systematic imaging surveillance with PET-CT scans is recommended for at least one to two years after treatment. Other cancers follow different schedules, but the pattern is similar: frequent checks early on, tapering off as time passes without recurrence.
Between scans, your oncologist will schedule regular office visits to check for symptoms, monitor bloodwork, and manage any lingering side effects from treatment.
Palliative and Supportive Care
Palliative care is not the same as stopping treatment. It can begin at any point during cancer care, including alongside chemotherapy, targeted therapy, or immunotherapy. The focus is on managing symptoms like pain, fatigue, nausea, shortness of breath, and insomnia, while also addressing the emotional, spiritual, and practical challenges that come with a cancer diagnosis.
Palliative care teams also support caregivers, who often face their own physical and emotional strain. They can help with financial concerns, insurance questions, advance care planning, and communication between family members and the medical team. If the point comes where curative treatment is no longer the goal, palliative care helps with the transition to hospice, which focuses entirely on comfort and quality of life.